Henderson Jane 4

What Happened
Jane Henderson, Chief Financial Officer of Apogee Therapeutics (APGE), sold 2,000 shares of company stock in an open-market transaction on April 16, 2026. The shares were disposed at $90.00 per share for a total transaction value of $180,000. This transaction is a sale (routine disposition) rather than a purchase.

Key Details

• Transaction date and price: 2026-04-16 — 2,000 shares sold at $90.00 each (total $180,000).
• Filing date: Form 4 filed 2026-04-17 (appears timely; Form 4 is typically due within two business days).
• Shares owned after transaction: Not specified in the information provided.
• Footnote: Transaction executed pursuant to a Rule 10b5-1 trading plan adopted September 2, 2025. (F1)
• Accession: 0001104659-26-045062.

Context
Trades executed under a Rule 10b5-1 plan are pre-arranged and are commonly used by insiders to sell shares on a set schedule; such sales are often routine and do not by themselves indicate a change in insider sentiment. This filing documents a sale, which is generally less informative than insider purchases for assessing bullish conviction.